Results 231 to 240 of about 554,589 (315)

Cortical effects of bromocriptine, a D-2 dopamine receptor agonist, in human subjects, revealed by fMRI [PDF]

, 2001
Daniel Y. Kimberg, Gustavo D. Aguirre, Jessica Lease, Mark D’Esposito   +3 more
openalex   +1 more source

The aporetic dialogues of Modena on gender differences: Is it all about testosterone? EPISODE I: CRIME

Andrology, EarlyView.
Abstract This is the first episode of a series of four discussions on the differences between males and females, in apparently non‐andrological fields. You will read the transcript of discussions that actually took place at the Endocrinology Unit in Modena, Italy, in the form of the aporetic dialogues of ancient Greece.
Giulia Brigante, Giulia D'Angelo, Vanessa Caccin, Silvia Coluccia, Immacolata Conte, Veronica Maria Demichelis, Rossana Cecchi, Manuela Simoni   +7 more
wiley   +1 more source

Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease. [PDF]

CNS Neurol Disord Drug Targets
Bezard E, Gray D, Kozak R, Leoni M, Combs C, Duvvuri S.   +5 more
europepmc   +1 more source

Morbid Obesity Due to Prolactinoma and Significant Weight Loss After Dopamine Agonist Treatment. [PDF]

AACE Clin Case Rep, 2021
Ali M, Mirza L.
europepmc   +1 more source

Ameliorating effect of dopamine D2 agonist on impairment of prepulse inhibition in aged rats.

, 1999
Taku Yamaguchi, Shigenori Watanabe, Tsuneyuki Yamamoto   +2 more
openalex   +1 more source

Kisspeptin as a test of hypothalamic dysfunction in pubertal and reproductive disorders

Andrology, EarlyView.
Abstract The hypothalamic–pituitary–gonadal axis is regulated by the gonadotropin‐releasing hormone pulse generator in the hypothalamus. This is comprised of neurons that secrete kisspeptin in a pulsatile manner to stimulate the release of GnRH, and, in turn, downstream gonadotropins from the pituitary gland, and subsequently sex steroids and ...
Aureliane C. S. Pierret, Aaran H. Patel, Elisabeth Daniels, Alexander N. Comninos, Waljit S. Dhillo, Ali Abbara   +5 more
wiley   +1 more source

Delayed Dopamine Agonist Withdrawal Syndrome After Deep Brain Stimulation for Parkinson Disease. [PDF]

Neurol Clin Pract, 2021
Jackowiak EM, Chou KL, Patil PG, Levin E, Leventhal D.   +4 more
europepmc   +1 more source

Erratum to “estimation of the interstitial free concentration of the putative dopamine D3 receptor selective agonist 7-OH-DPAT in the dorsal striatum of freely moving rats” [Neurosci. Lett. 193 (1995) 65–67]

, 1995
Raul R. Gainetdinov, Tatyana D. Sotnikova, Tatyana V. Grekhova, K.S. Rayevsky   +3 more
openalex   +1 more source

Long‐duration effect and the postsynaptic compartment: Study using a dopamine agonist with a short half‐life [PDF]

, 2001
Fabrizio Stocchi, Laura Vacca, Alfredo Berardelli, Francesca De Pandis, Stefano Ruggieri   +4 more
openalex   +1 more source

Commentary: Clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy. [PDF]

Front Endocrinol (Lausanne)
Andereggen L, Christ E.
europepmc   +1 more source